

## ***Basingstoke, Southampton and Winchester***

### ***District Prescribing Committee (DPC)***

#### **Recommendations of the meeting of 10<sup>th</sup> February 2015**

##### **Supported or limited support e.g. Specialist recommendation**

- **Alogliptin for type 2 diabetes mellitus** - This relatively new oral diabetes medication was supported for local use as the most cost-effective 'gliptin' option in primary care currently.
- **Rivaroxaban as a local option in the treatment of deep vein thrombosis (DVT)** - supported as an option within agreed local treatment pathways, as a more convenient alternative to low molecular weight heparin (LMWH) and warfarin. In suspected DVT clinicians may prescribe 15mg tablets twice daily for up to 7 days, supplied in a convenient 14 tablet original pack.

##### **Not supported currently**

- **Insulin degludec and liraglutide (IDegLira) combination (Xultophy®)** - This product is not supported for routine local use currently. It may be suitable for exceptional use but should be reserved for specialist only prescribing (i.e. 'red') at this stage.

##### **Other Information/ Reminders**

- **Buprenorphine patches and safety advice** - There are now 3 different brands available, offering different strengths of buprenorphine as well as different durations of action. See BNF no 68 (page 281) for full product details. A reminder that these products are not recommended for first line use locally when opioids are being considered either for moderate or severe pain. When prescribed the particular **brand** should be specified to avoid confusion and reduce the risk of dosing errors.
- **Inhaler devices for COPD** - There is an increasingly large choice of inhalers available, with another 3 combination products recently launched. The DPC has requested local specialist review, with a list of preferred devices and products to guide primary care, recognising that choice of device can be imperative to aid compliance. Further guidance will follow. In the meantime clinicians should be mindful to check ongoing clinical response to the inhaled medication(s) and choose the device that best suits the individual patient.
- **Nepafenac eye drops following cataract surgery in patients with diabetes** - The DPC agreed that any agreed niche use of this new product should be managed in the specialist ophthalmology setting. GPs should not be asked to prescribe.
- **Acamprosate shared care guidelines** - the DPC noted the updated guidelines from Southern Health FT and Solent NHS Trust, available at <http://www.southernhealth.nhs.uk/knowledge/medicines-management/policies/?p=1>
- **Antipsychotic prescribing guidelines** - the DPC noted the updated guidelines from Southern Health, available via the above weblink
- **Anxiety treatment guidelines for adults** - the DPC noted the updated guidelines from Southern Health FT and Solent NHS Trust, available via the above weblink.

##### **Summarised on behalf of the District Prescribing Committee**

**Julia Bowey (Southampton City CCG) 17.02.15**